

Get to Know the Immunologists
Behind the Papers You Read



View Profiles



T Cell Recognition of Distinct Peptide:I-A^u Conformers in Murine Experimental Autoimmune Encephalomyelitis

This information is current as of January 22, 2018.

Jason C. Huang, Mei Han, Alfredo Minguela, Silvia Pastor, Ayub Qadri and E. Sally Ward

J Immunol 2003; 171:2467-2477; ;
doi: 10.4049/jimmunol.171.5.2467
<http://www.jimmunol.org/content/171/5/2467>

Why *The JI*?

- **Rapid Reviews! 30 days*** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Speedy Publication!** 4 weeks from acceptance to publication

**average*

References This article **cites 81 articles**, 38 of which you can access for free at:
<http://www.jimmunol.org/content/171/5/2467.full#ref-list-1>

Subscription Information about subscribing to *The Journal of Immunology* is online at:
<http://jimmunol.org/subscription>

Permissions Submit copyright permission requests at:
<http://www.aai.org/About/Publications/JI/copyright.html>

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at:
<http://jimmunol.org/alerts>

The Journal of Immunology is published twice each month by
The American Association of Immunologists, Inc.,
1451 Rockville Pike, Suite 650, Rockville, MD 20852
Copyright © 2003 by The American Association of
Immunologists All rights reserved.
Print ISSN: 0022-1767 Online ISSN: 1550-6606.



T Cell Recognition of Distinct Peptide:I-A^u Conformers in Murine Experimental Autoimmune Encephalomyelitis¹

Jason C. Huang,* Mei Han,* Alfredo Minguela,*[†] Silvia Pastor,* Ayub Qadri,^{2*} and E. Sally Ward^{3*}

We have used T cells bearing TCRs that are closely related in sequence as probes to detect conformational variants of peptide-MHC complexes in murine experimental autoimmune encephalomyelitis in H-2^u mice. The N-terminal epitope of myelin basic protein (MBP) is immunodominant in this model. Our studies have primarily focused on T cell recognition of a position 4 analog of this peptide (MBP1–9[4Y]) complexed with I-A^u. Using site-directed mutagenesis, we have mapped the functionally important complementarity determining region residues of the 1934.4 TCR V α domain. One of the resulting mutants (Tyr⁹⁵ to alanine in CDR3 α , Y95A) has interesting properties: relative to the parent wild-type TCR, this mutant poorly recognizes Ag complexes generated by pulsing professional APCs (PL-8 cells) with MBP1–9[4Y] while retaining recognition of MBP1–9[4Y]-pulsed unconventional APCs or insect cell-expressed complexes of I-A^u containing tethered MBP1–9[4Y]. Insect cell expression of recombinant I-A^u with covalently tethered class II-associated invariant chain peptide or other peptides which bind relatively weakly, followed by proteolytic cleavage of the peptide linker and replacement by MBP1–9[4Y] *in vitro*, results in complexes that resemble peptide-pulsed PL-8 cells. Therefore, the distinct conformers can be produced in recombinant form. T cells that can distinguish these two conformers can also be generated by the immunization of H-2^u mice, indicating that differential recognition of the conformers is observed for responding T cells *in vivo*. These studies have relevance to understanding the molecular details of T cell recognition in murine experimental autoimmune encephalomyelitis. They are also of particular importance for the effective use of multimeric peptide-MHC complexes to characterize the properties of Ag-specific T cells. *The Journal of Immunology*, 2003, 171: 2467–2477.

T cell receptors ($\alpha\beta$) expressed by CD4⁺ cells recognize complexes of antigenic peptides bound to MHC class II proteins on the surface of APCs. A complex series of events is involved in the loading of antigenic peptides derived from exogenous proteins onto MHC class II molecules. Newly synthesized MHC class II proteins egress the endoplasmic reticulum (ER)⁴ in association with invariant chain (Ii) (1). These complexes traffic into specialized compartments called multivesicular late endosomes (MIIC) or class II vesicles (CIIV) (2, 3), where Ii is proteolysed to leave peptides encompassing Ii residues 81–104 (class II-associated Ii peptide (CLIP)) in the Ag binding groove of the MHC class II molecule (4, 5). CLIP occupancy of the groove prevents loading by peptides in the ER or Golgi before trafficking

of the class II molecule into MIIC compartments (6, 7). In MIIC compartments CLIP is displaced by antigenic peptides derived from exogenous Ag, in concert with the peptide editing functions of H2-M (8–10). Peptide editing by H2-M ensures that stably bound peptides are selectively bound to the MHC class II groove. These “mature” peptide-MHC (pMHC) complexes are subsequently transported to the cell surface by either vesicular transport (11) or secreted as exosomes (12). Alternatively, MHC class II presentation of peptide or partially denatured Ags can occur via an Ii independent route, which involves either direct loading on the cell surface or recycling of MHC class II molecules from the cell surface into endocytic vesicles (13–16).

Multiple studies have demonstrated that MHC class II molecules are highly flexible and can exist in distinct conformational states which may have different stabilities and propensities to bind peptide (17–23). For example, Ii coexpression affects the conformation of surface MHC class II molecules (24–26) and variations in conditions for *in vitro* loading of peptide can affect the proportions and stabilities of pMHC isomers present (18–22, 27, 28). Studies have also shown that distinct pMHC complexes can be formed depending on the route of Ag loading (29–32): intracellular processing of Ag results in complexes that have been designated type A by Unanue and colleagues (29, 30, 32), whereas peptide pulsing generates type B complexes. Subsets of Ag-specific T cells can distinguish between these complexes (29–32). The generation of type A complexes in intracellular acidic vesicles in the presence of H2-M, in contrast to type B complexes which are produced by loading on the cell surface or in less acidic recycling vesicles, has led to the suggestion that type A complexes may be less flexible than those of the type B class (32, 33). In addition, Janeway and colleagues (34) have shown that pMHC complexes can exist in at least two distinct conformations on the surface of

*Center for Immunology and Cancer Immunobiology Center, University of Texas Southwestern Medical Center, Dallas, TX 75390; and [†]Seccion de Inmunologia, Hospital Universitario Virgen de la Arrixaca, El Palmar, Murcia, Spain

Received for publication October 8, 2002. Accepted for publication June 24, 2003.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported by grants from the National Institutes of Health (R01 AI/NS 42949) and National Multiple Sclerosis Society (RG-2411). A.M. was supported by a fellowship from the Fondo de Investigacion Sanitaria (FIS-00/5030 and 01/5037).

² Current address: National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, India.

³ Address correspondence and reprint requests to Dr. E. Sally Ward, Center for Immunology, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390-9093. E-mail address: Sally.Ward@Utsouthwestern.edu

⁴ Abbreviations used in this paper: ER, endoplasmic reticulum; Ii, invariant chain; MIIC, multivesicular late endosome; CLIP, class II-associated Ii peptide; pMHC, peptide-MHC; CDR, complementarity determining region; EAE, experimental autoimmune encephalomyelitis; MBP, myelin basic protein; RDP, rabies-derived peptide; WT, wild type; LN, lymph node; tg, transgenic; CD62L, CD62 ligand.

APCs that can be distinguished by reactivity with the anti-I-A^b Ab, 25-9-17. The properties of the bound peptide appear to play a central role in inducing these two conformers which can be distinguished by T cells (34). Thus, both the route of presentation and the properties of the antigenic peptide can affect T cell recognition, and this has obvious implications for fundamental aspects of T cell biology such as tolerance induction (30, 33–35).

In the current study, we have used T cells bearing TCRs that are closely related in sequence as probes to detect conformational variants of pMHC complexes. Although recent structural studies have given valuable insight into the molecular nature of TCR-pMHC interactions (36–40), there is a paucity of data concerning the functional contribution of individual TCR residues to Ag recognition. Knowledge of this is of central relevance to understanding T cell activation. In this study, we have investigated the contribution of exposed complementarity determining region (CDR) residues of the 1934.4 TCR V α domain to the recognition of Ag. The V α domain of this TCR was chosen for two reasons: first, the x-ray structure of this V α domain has been solved (41), allowing mutations to be chosen that would minimize perturbation of the V α domain fold. Second, in other TCR-pMHC systems, both structural and functional studies have demonstrated a dominant role for the TCR V α domain in Ag recognition (37–40, 42, 43).

The 1934.4 TCR is derived from a T cell clone that is associated with the mouse model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE) (44, 45). The relevant Ag in this system is the immunodominant N-terminal (acetylated) epitope of myelin basic protein (MBP), MBP1–9, associated with the MHC class II protein, I-A^u (46). We have systematically mutated the 1934.4 CDR α residues. The effect of the mutations on T cell responsiveness has been assessed and a map of functionally important residues generated. Significantly, our analyses reveal that mutation of residue 95 of CDR3 α results in a TCR that can distinguish between pMHC complexes expressed in unconventional (T cells, insect cells) vs professional APCs. We show that a complex resembling the pMHC conformer on the surface of professional APCs can be generated by “forcing” association of the Ii-derived peptide, CLIP, or other irrelevant peptide with the I-A^u molecule during biosynthesis followed by displacement with antigenic peptide *in vitro*. These studies have led to a detailed characterization of the types of pMHC conformers that can be produced under distinct conditions of Ag loading and how these might be used to distinguish subsets of Ag-specific T cells in murine EAE. Our observations also have obvious relevance to the analysis of Ag-specific T cells using recombinant, multimeric pMHC complexes.

Materials and Methods

Mice, cell lines, Abs, and peptides

Mice transgenic for the β -chain of the 172.10 TCR (47) were generously provided by Dr. J. Goverman (University of Washington, Seattle, WA). The I-A^u-expressing B cell line, PL-8 (48) was kindly provided by Dr. D. Wraith (University of Bristol, Bristol, U.K.). The I-A^u-transfected derivative of BW5147, Utm6.15 (49), was a generous gift of Dr. H. McConnell (Stanford University, Stanford, CA). Cell lines expressing the 1934.4 TCR were made by transfecting TCR genes into a CD4⁺, TCR⁺ cell line 58 α ⁺ β ⁺. This TCR-negative derivative of BW5147 was kindly provided by Dr. S. Hedrick (University of California, San Diego, CA) with permission from Dr. B. Malissen (Institut National de la Santé et de la Recherche Médicale-Centre National de la Recherche Scientifique, Marseille-Luminy, France). The T cell hybridomas HRC.1 and HCQ.4 (50) recognize type II collagen residues 256–270 associated with I-A^g and were a generous gift of Dr. R. Holmdahl (Lund University, Lund, Sweden). PE/FITC-labeled anti-TCR C β (H57-597), PE-labeled anti-TCR V β 8 (F23.1), PerCP-labeled anti-CD4 (RM4-5), allophycocyanin-labeled anti-CD62 ligand (CD62L) (MEL-14), PE/FITC-labeled anti-V α 2 (B20.1), and a hamster isotype-matched control (for H57-597 staining) were purchased from BD Pharmingen (San Diego, CA). The N-terminal peptide of murine MBP

(MBP1–9, ASQKRPSQR, acetylated at residue 1) and (acetylated) analogues MBP1–9[4Y], MBP1–9[3F,4Y], MBP1–9[3H,4Y], MBP1–9[3M,4Y], and MBP1–9[3Y,4Y] were synthesized at the Peptide Synthesis Unit of the Howard Hughes Medical Institute (University of Texas Southwestern Medical Center, Dallas, TX).

Generation of T cell transfectants

The 1934.4 TCR α - and β -chain expression vectors used for transfections were constructed using α and β shuttle vectors (generously provided by Dr. M. Davis, Stanford University) and have been described previously (51). Site-directed mutagenesis to mutate residues 29 (CDR1), 51, 52, 53 (CDR2), and 94, 95 (CDR3) of the V α domain was conducted using splicing by overlap extension and mutated PCR products were recloned as described (51). Tyr²⁹ was mutated to alanine or phenylalanine (Y29A, Y29F), Arg⁵¹ was mutated to alanine or lysine (R51A or R51K), Asp⁵² was mutated to alanine or glutamic acid (D52A, D52E), and Lys⁵³, Asn⁹⁴, and Tyr⁹⁵ were mutated to alanine (K53A, N94A, and Y95A). Sequences of oligonucleotides are available upon request. All constructs were cloned into the α shuttle vector and sequenced before use in transfections. 58 α ⁺ β ⁺ cells were transfected with full-length TCR constructs by electroporation and stable transfectants selected as described (51). Clones were assayed for surface expression using PE-labeled H57-597 (anti-C β) and PE-labeled F23.1 (anti-V β 8).

Production of soluble pMHC complexes

Soluble, recombinant MBP1–11:I-A^u (4K:I-A^u) and MBP1–11[4Y]:I-A^u (4Y:I-A^u) complexes were generated and purified using baculovirus-infected High-Five cells (52). Codons encoding the wild-type (WT) MBP1–11 peptide (lysine at position 4, “4K”) or a position 4 analog (lysine to tyrosine; “4Y”) of MBP1–11 were covalently tethered to I-A β ^u via flexible peptide linkers (53). The immunodominant MBP epitope requires acetylation for recognition (46). The N termini of the peptides were therefore extended with a glycine which mimics the acetyl group (54). The 4Y analog was used for the majority of the studies as this peptide binds more tightly to I-A^u than the WT peptide (49, 55, 56) and recombinant complexes made with the WT peptide are significantly less stable (44).

To generate CLIP:I-A^u complexes, codons encoding CLIP84–101 (57) followed by a rhinovirus 3C protease cleavage site (Leu-Glu-Val-Leu-Phe-Gln-Gly-Pro) were engineered into a unique *KpnI* site in the I-A^u expression construct (53). The CLIP peptide-protease cleavage site codons were inserted on the 5' side of a sequence encoding a flexible linker, Gly-Ser-Gly-Ser-Gly-Ser-Gly, which is appended to the N terminus of the β ^u polypeptide (53). This resulted in tethering of the CLIP sequence to the N terminus of the β ^u chain via a rhinovirus 3C cleavage site, using an analogous strategy to that used for 4Y:I-A^u complexes (52). CLIP:I-A^u complexes were purified from baculovirus-infected High-Five cells using Talon Superflow resin (Clontech Laboratories, Palo Alto, CA) followed by Y3P Sepharose as described (53). Purified material was digested with PreScission Protease (rhinovirus 3C protease; Amersham Biosciences, Piscataway, NJ) as recommended by the manufacturer. During the digestion, either MBP1–9[4Y] or OVA323–339 were added in a 10-fold molar excess over CLIP:I-A^u. OVA323–339 binds tightly to I-A^u (56). Protease was removed by addition of glutathione-Sepharose (20 μ l per 2 μ g of protease). Pefabloc (Roche Applied Science, Indianapolis, IN) was added to a final concentration of 4 mM to the proteolysed peptide-I-A^u complexes. Empty I-A^u molecules, or molecules with only weakly bound peptide, are unstable (49, 53). Therefore, proteolysed peptide:I-A^u complexes were stored in the presence of 50 μ g/ml MBP1–9[4Y] or OVA323–339 (as appropriate) to minimize the generation of empty molecules by peptide dissociation. MBP68–80:I-A^u and rabies-derived peptide-1 (RDP-1):I-A^u complexes were generated using an analogous approach to that used for CLIP:I-A^u. The amino acid sequences of the two peptides are MBP68–80 (Tyr-Gly-Ser-Leu-Pro-Gln-Lys-Ser-His-Gly-Arg-Thr-Gln) and RDP-1 (Gln-Val-Val-Ala-Leu-Lys-Pro-Ala-Ile-Ala-Ala-Ala) (56).

T cell activation assays

T cell transfectants or hybridomas (5 \times 10⁴ cells/well) were incubated with APCs (5 \times 10⁴ cells/well) pulsed with MBP1–9 or analogues. PL-8, Utm6.15 cells, or I-A^u-expressing splenocytes were used as APCs in these assays. Transfectants (5 \times 10⁴ cells/well) were also stimulated with plate-bound anti-CD3 ϵ (145-2C11), 4Y:I-A^u, 4K:I-A^u, CLIP:I-A^u (or modified variants), MBP68–80:I-A^u (or modified variants), and RDP-1:I-A^u (or modified variants) complexes as described (52, 58). Additional peptide (MBP1–9[4Y] or OVA323–339) was added at 10 μ g/ml both during and following coating with proteolysed, peptide-loaded CLIP:I-A^u, MBP68–80:I-A^u, and RDP-1:I-A^u complexes as appropriate. Cells were stimulated in duplicates or triplicates for 24 h and IL-2 levels in culture supernatants were

quantitated by IL-2 ELISA (58). For each experiment shown, averages of duplicate or triplicate data points are plotted. For duplicates and triplicates, 85% of the SDs were <20% and 15% of the average values, respectively. The numbers of repeats for each experiment are shown in the figure legends.

Analysis of tetramer staining of transfectants and hybridomas

4Y:I-A^u complexes were generated as described (53). Tetramer staining was conducted at 37°C. PE-labeled anti-TCR β -chain Ab, H57-597, and anti-TCR V β 8/Ab, F23.1, were used to normalize tetramer staining levels for TCR expression levels (53, 59).

Generation of T cell hybridomas

Male 172.10 TCR β -chain transgenic mice (47) were immunized s.c. (footpad and tail base) with 200 μ g of MBP1-9[4Y] in CFA supplemented with 4 mg/ml *Mycobacterium tuberculosis* strain H37RA (Difco, Detroit, MI). Ten days following immunization, splenocytes and lymph node (LN) cells were extracted and expanded using 50 μ g/ml MBP1-9. Following 4 days of expansion, cells were fused with TCR-negative BW5147 cells (American Type Culture Collection, Manassas, VA) and hybridomas were selected as described (60). Sequences of TCR V α and V β domain genes were analyzed using RT-PCR and standard methods.

Ex vivo analysis of Ag-specific T cells

172.10 TCR β -chain transgenic mice were immunized as above. Expression of CD62L by Ag (MBP1-9[4Y]:I-A^u) specific CD4⁺ T cells in draining LNs was monitored before immunization and on days 3, 5, 7, and 11 postimmunization. Four color staining of 4×10^6 LN cells was performed in two steps: PE-labeled 4Y:I-A^u tetramers, PerCP-labeled anti-CD4 and allophycocyanin-labeled anti-CD62L Abs were added simultaneously at 37°C for 30 min. Following a wash in PBS, cells were incubated with FITC-labeled anti-V α 2 Ab at 4°C for 30 min (this two-step staining procedure was necessary to avoid partial blockade of tetramer staining by anti-V α 2). Stained cells were analyzed using a FACSCalibur (BD Biosciences, Mountain View, CA), and data were analyzed using CellQuest (BD Biosciences) and WinMDI 2.8 (<http://facs.scripps.edu>).

Results

Generation and analysis of Ag responsiveness of TCR transfectants

We first conducted a systematic analysis of the effects of mutating the CDR residues of the 1934.4 V α domain on Ag recognition. These residues are shown on the 1934.4 V α domain structure (Fig. 1; Ref. 41). Initially, CDR1 (Y29), CDR2 (R51, D52, and K53), and CDR3 (N94 and Y95) residues were each mutated to alanine.

Although cotransfection of the corresponding α shuttle constructs for K53A (Lys⁵³ to alanine), N94A, and Y95A with the WT 1934.4 β shuttle construct resulted in surface expression of the corresponding TCRs, this was not the case for Y29A, R51A, and D52A. These latter TCRs were expressed at undetectable levels (not shown). Therefore, more conservative mutations of these residues were made (Y29F, R51K, and D52E). Transfectants expressing surface TCR were obtained for both R51K and D52E, whereas transfectants bearing detectable levels of Y29F could not be obtained. This lack of expression precluded analysis of the effect of mutating this CDR1 α residue. Transfectants expressing TCRs with mutations in CDRs 2 and 3 that expressed similar levels of surface TCR (data not shown) were used in further analyses.

The responsiveness of the TCR transfectants to a position 4 analog of the N-terminal epitope of MBP, MBP1-9[4Y], complexed with I-A^u, was analyzed. The MBP1-9[4Y] analog was used with a position 4 substitution of lysine by tyrosine; this results in a peptide that binds to I-A^u with 10³- to 10⁵-fold higher affinity than the WT peptide, MBP1-9 (49, 55, 56). The position 4 substitution does not affect the disposition of T cell contacts (48, 61). As APCs, a line (PL-8) made by fusing I-A^u splenocytes with the I-A-negative B lymphoma M12.C3 was used (48). For each mutation, several transfectants were made and representative data for one transfectant for each TCR type is shown (Fig. 1). The analyses indicated that the mutations in CDR2 and CDR3 affect Ag recognition to varying degrees: K53A has an intermediate effect, whereas the activity of R51K, D52E, and Y95A are markedly decreased relative to transfectants expressing the WT 1934.4 TCR. N94A does not produce detectable amounts of IL-2 at any Ag dose. Significantly, all transfectants show similar responses to plate-bound anti-CD3 ϵ (145-2C11), indicating that the machinery for signaling is intact (Fig. 1).

Analysis of the avidity of the TCR-pMHC interactions

Binding of multimeric pMHC ligands to Ag-specific T cells can be used to assess the avidity of the corresponding TCR-pMHC interaction (59, 62–64). Therefore, we analyzed the binding of multimeric (tetrameric) 4Y:I-A^u complexes to the WT and mutant transfectants (Fig. 2). The 4Y:I-A^u complexes comprise a position 4




FIGURE 1. Residues of the 1934.4 TCR V α domain targeted for mutagenesis and effects on responsiveness of the corresponding TCR transfectants. *A*, α -Carbon trace of the 1934.4 V α domain (top view with predicted pMHC interaction surface coplanar with image). CDR residues targeted for mutagenesis are shown in black. The figure was drawn using RASMOL (courtesy of R. Sayle, Bioinformatics Research Institute, University of Edinburgh, Edinburgh, U.K.). *B* and *C*, IL-2 levels following stimulation of transfectants expressing WT or mutated TCRs with plate-bound anti-CD3 ϵ (145-2C11) (*B*) or MBP1-9[4Y]-pulsed PL-8 cells (*C*). Data are representative of at least four independent experiments.




FIGURE 2. Staining of the TCR transfectants with fluorescently labeled 4Y:I-A^u tetramers. *A*, Transfectants were incubated with extravidin-PE-labeled 4Y:I-A^u complexes or PE-labeled F23.1 (anti-Vβ8). Histogram plots for WT and Y95A transfectants are shown. Filled histograms represent fluorescence levels for cells treated with extravidin-PE only (for tetramer staining) or isotype control (for F23.1). *B*, Normalized tetramer staining for WT and mutant transfectants. Cells were stained with extravidin-PE labeled 4Y:I-A^u tetramers or PE-labeled F23.1 as in *A*. The ratios of mean fluorescence intensities for staining with tetramers to F23.1 are shown. Data are representative of four independent experiments.

analog (Lys to Tyr) of the N-terminal epitope of MBP covalently tethered to I-Aβ^u, in association with I-Aα^u (53). To account for slight differences in TCR expression, tetramer staining was nor-

malized for expression levels. Generally, a good correlation between Ag responsiveness (Figs. 1 and 2) and staining intensity was obtained. However, the Y95A transfectant is an exception. Despite the low Ag responsiveness of this transfectant (Fig. 1), it consistently stained to slightly higher (normalized) levels than WT transfectants with the multimeric Ag complexes (Fig. 2B). This suggested that the Y95A TCR might sense conformational differences between I-A^u expressed in B cells and in insect cells (the host used to make our recombinant 4Y:I-A^u complexes) or other unconventional APCs. Alternatively, the Y95A TCR might bind relatively strongly to recombinant 4Y:I-A^u complexes due to the presence of additional favorable interactions with the linker peptide tethering the MBP peptide to I-Aβ^u (53) (including two extra MBP residues in the MBP1-11[4Y] sequence used to make the recombinant complexes). To distinguish between these possibilities, the responsiveness of the transfectants to both MBP1-9[4Y]-pulsed Utm6.15 cells (unconventional APCs comprising a T cell line transfected with I-A^u (49)) and plate-bound 4Y:I-A^u complexes was assessed. For both Utm6.15-presented peptide and recombinant pMHC complexes, a relationship between multimer staining and responsiveness was seen (Fig. 3). Notably, for all transfectants except Y95A, responsiveness in these assays showed a similar pattern to that seen for Ag-pulsed PL-8 cells (Fig. 1). In an earlier study, we have also shown that the conformational-dependent Ab Y3P stains I-A^u on the surface of PL-8 and Utm6.15 cells to similar levels (65), demonstrating that at least in the vicinity of the Y3P interaction site there are no large conformational differences between the I-A^u molecules expressed on these distinct cell types.

The responses of the transfectants to MBP1-9 (WT MBP peptide, 4K)-pulsed Utm6.15 cells were also analyzed (Fig. 3). The lower affinity of this peptide for I-A^u results in shifts of the dose response curves to higher Ag doses (48). Again, Y95A transfectants were more responsive to Ag than WT cells. Taken together, the data show that the linker peptide in the recombinant 4Y:I-A^u




FIGURE 3. Responses of the TCR transfectants to Ag generated in professional vs unconventional APCs. IL-2 levels following stimulation of transfectants expressing WT or mutated TCRs with: *A*, MBP1-9[4Y]-pulsed Utm6.15 cells; *B*, plate-bound, recombinant 4Y:I-A^u complexes; *C*, MBP1-9 (WT peptide with lysine at position 4)-pulsed Utm6.15 cells; *D*, MBP1-9[4Y]-pulsed I-A^u splenocytes. Data are representative of at least four independent experiments.

complexes does not contribute to the enhanced recognition of recombinant 4Y:I-A^u by the Y95A TCR. In addition, analysis of the responses of WT and Y95A cells to Ag-pulsed, I-A^u splenocytes showed that WT cells are more responsive to this form of Ag, recapitulating the pattern seen with the lymphoblastoid line, PL-8 (Figs. 1 and 3).

Analysis of the differences between Ag generated in professional vs unconventional APCs

The differences in patterns of responsiveness of WT and Y95A transfectants to MBP1-9 (or MBP1-9[4Y]) complexed with I-A^u from professional vs unconventional APCs prompted us to further investigate possible reasons for conformational variation of the pMHC ligand. Treatment of APCs with the lysosomotropic agent, chloroquine, had minor effects on Ag presentation to WT or Y95A transfectants, and the effect was similar for both cell types (data not shown). This indicates that for both PL-8 and Utm6.15 cells, peptide loading occurs primarily on the cell surface or in early (neutral) endosomes rather than in acidified endosomal compartments. Therefore, the two conformers of I-A^u are not a secondary consequence of peptide loading in different intracellular environments.


An obvious difference between professional and unconventional APCs is that the latter do not express Ii chain (verified for Utm6.15 cells by immunoblotting; data not shown). To investigate a possible role for Ii-derived CLIP in inducing the different I-A^u conformers, we first transfected Utm6.15 cells with an Ii expression construct with the aim that they would become "PL-8 like." However, despite the analysis of multiple Utm6.15 transfectants, the expression of Ii was always significantly less than that in PL-8 cells, precluding the validity of their use in such studies. Therefore, we took an alternative, more direct approach of expressing recombinant I-A^u with covalently tethered CLIP. This approach would have the advantage that it would also exclude any contribution from the known trafficking functions of Ii through, for example, its transmembrane domain. In the expression construct, the linker peptide connecting CLIP to the β^u polypeptide contained a recognition site for rhinovirus 3C protease, allowing site-specific cleavage of the tether following purification. CLIP:I-A^u complexes were treated with protease in the presence of an excess of MBP1-9[4Y] with the aim of displacing CLIP by the MBP peptide. Simulta-

neous proteolysis and peptide loading were conducted to minimize loss of activity of empty I-A^u molecules which are known to be unstable (49). Cleavage and peptide loading were conducted at pH 7.0 as this pH is optimal for the protease activity. Furthermore, the lack of a significant effect of chloroquine on MBP1-9[4Y] presentation indicates that peptide loading onto APCs occurs at near neutral pH, and we aimed to mimic these conditions. Proteolysis appeared to be complete, as assessed by a mobility shift using SDS-PAGE (Fig. 4).

Recombinant, cleaved CLIP:I-A^u loaded with MBP1-9[4Y] (designated CLIP/4Y:I-A^u) was immobilized on plastic and used to stimulate WT and Y95A transfectants. The pattern of stimulation was essentially the same as that induced by Ag-pulsed PL-8 cells, with Y95A cells being significantly less responsive than WT transfectants (Figs. 1 and 4). This pattern contrasts with the hierarchy of responsiveness induced by plate-bound 4Y:I-A^u complexes expressed in the absence of CLIP preassociation (Fig. 4). In addition, consistent with the inability of K53A transfectants to distinguish pMHC on PL-8 vs Utm6.15 cells (Figs. 1 and 3), these cells showed similar responses to 4Y:I-A^u complexes made with and without CLIP prebinding (data not shown).

To exclude the possibility that the difference in stimulatory properties between 4Y:I-A^u and CLIP/4Y:I-A^u were due to the incubation conditions used during protease cleavage, 4Y:I-A^u complexes were incubated in protease digestion buffer in the presence and absence of added protease. These pretreatments did not affect their stimulatory properties (data not shown). Undigested CLIP:I-A^u complexes showed no stimulatory activity (Fig. 4). Furthermore, CLIP/OVA:I-A^u complexes were generated by cleavage of CLIP followed by loading with OVA peptide residues 323-339 (OVA323-339) which are known to bind to I-A^u (56). CLIP/OVA:I-A^u complexes did not stimulate either WT or Y95A transfectants, demonstrating that the response is specific for peptide (Fig. 4). Finally, in the absence of protease cleavage, CLIP could not be displaced by exogenously added MBP1-9[4Y] to generate complexes that could be recognized by the WT and Y95A transfectants (data not shown). The data show that CLIP binding to I-A^u, followed by displacement by MBP1-9[4Y], results in a pMHC

FIGURE 4. Properties of CLIP:I-A^u complexes and their peptide (MBP1-9[4Y] or OVA323-339) loaded derivatives. **A**, Fifteen-percent PAGE analysis of undigested CLIP:I-A^u complexes and complexes generated by rhinovirus 3C protease digestion followed by loading with OVA323-339 or MBP1-9[4Y] (CLIP/OVA:I-A^u and CLIP/4Y:I-A^u, respectively). Molecular masses (in kilodaltons) are indicated on the right margin. **B-E**, IL-2 levels were quantitated following stimulation of transfectants expressing WT or Y95A TCR with: **B**, plate-bound, recombinant 4Y:I-A^u complexes; **C**, plate-bound CLIP/4Y:I-A^u complexes; **D**, plate-bound, undigested CLIP:I-A^u complexes; **E**, plate-bound CLIP/OVA:I-A^u complexes. The HRC.1 hybridoma (50) was used as a negative control. Data are representative of five independent experiments for **B**, **C**, and **E** and two for **D**.



complex that is representative of complexes generated by pulsing professional APCs with the same MBP peptide.

Recognition of the I-A^u conformers by T cells from H-2^u mice

We further investigated the recognition of the two types of MBP1-9[4Y]:I-A^u complexes by hybridomas made by immunizing 172.10 TCR β -chain transgenic (172.10 β tg) mice (47) with MBP1-9[4Y]. The presence of the transgenic β -chain in these mice restricts the diversity of the TCRs borne by responding T cells to receptors comprising the 172.10 β -chain paired with different endogenous α chains, with a strong bias toward V α 2 usage (43) which is the V α -chain of the 172.10 TCR (66). We compared the stimulation of the hybridomas with plate-bound 4Y:I-A^u complexes, CLIP/4Y:I-A^u complexes, MBP1-9[4Y]-pulsed Utm6.15 cells (unconventional APCs), and MBP1-9[4Y]-pulsed splenocytes (professional APCs) (Fig. 5). The majority of hybridomas responded similarly to both types of pMHC complexes (Fig. 5 and not shown). Consistent with their responses to plate-bound, recombinant 4Y:I-A^u, hybridomas 2, 10, and 20 showed similar levels of staining with 4Y:I-A^u tetramers (data not shown). However, hybridoma 20 showed a relatively poor response to CLIP/4Y:I-A^u complexes or MBP1-9[4Y]-pulsed splenocytes relative to plate-bound 4Y:I-A^u complexes or MBP1-9[4Y]-pulsed Utm6.15 cells. Therefore, the behavior of hybridoma 20 resembles that of Y95A cells.

The "CLIP/4Y:I-A^u responsive" hybridomas are V α 2⁺ and, as expected from the studies of others of V α 2⁺ cells in 172.10 β tg mice (43), expressed TCRs that are either the same or very similar in sequence to that of the 172.10 $\alpha\beta$ TCR (Fig. 5 and not shown). In contrast, hybridoma 20 is V α 2⁻ and expresses a TCR compris-

ing V α 4.2-J α 39. This V α domain is closely related (one residue difference: Pro to Ala in CDR3) to the 214.12 hybridoma isolated from MBP-immunized B10.PL mice (66) and shares the same V α usage with the 1934.4 TCR V α . The junctional region of the α -chain of hybridoma 20 is also closely related to that of the 172.10 hybridoma (Fig. 5).

We further investigated the properties of 4Y:I-A^u-specific T cells in 172.10 β tg mice. In naive mice, two similarly sized populations (V α 2⁺ and V α 2⁻) of CD4⁺ cells which stain with 4Y:I-A^u tetramers can be detected (Fig. 6). A comparative analysis of both the expansion and activation (assessed by CD62L down-regulation) of these two populations following immunization of 172.10 β tg mice with MBP1-9[4Y] indicates that V α 2⁻ cells are significantly less responsive to MBP1-9[4Y] *in vivo* than V α 2⁺ cells. Thus, the properties of the V α 2⁺ and V α 2⁻ populations appear to be recapitulated by the hybridomas. Despite the relatively poor activation/expansion of the V α 2⁻ population in 172.10 β tg mice, Ag-specific V α 2⁻ cells can apparently be rescued following *in vitro* expansion and fusion to make hybridomas. However, consistent with the low responsiveness of the V α 2⁻ T cells, the isolation of such hybridomas is a relatively rare event (1 in ~20 hybridomas).

Assessing the peptide specificity of the effects of CLIP prebinding

To assess whether the effects of CLIP prebinding were specific to the CLIP peptide, two additional recombinant peptide:I-A^u complexes were made in which two peptides of known relative affinities were tethered to I-A β ^u by a rhinovirus 3C protease cleavable linker. These peptides, RDP-1 and MBP68-80, bind to I-A^u with




FIGURE 5. Analysis of representative hybridomas from 172.10 TCR β -chain tg mice immunized with MBP1-9[4Y]. *A*, Flow cytometric analysis of TCR expression of representative hybridomas (2, 10, and 20) using PE-labeled anti-TCR V α 2 and FITC-labeled anti-TCR C β (H57-597). *B–E*, IL-2 levels following stimulation of hybridomas with: *B*, plate-bound 4Y:I-A^u complexes; *C*, plate-bound CLIP/4Y:I-A^u complexes generated by rhinovirus 3C protease cleavage of CLIP:I-A^u complexes and replacement of CLIP by MBP1-9[4Y]; *D*, MBP1-9[4Y]-pulsed Utm6.15 cells; *E*, MBP1-9[4Y]-pulsed I-A^u splenocytes. The HCQ.4 hybridoma (50) was used as a negative control. *F*, Amino acid sequences of the junctional regions of the V α domains of hybridomas used in *A–E*. J α usage for all hybridomas shown is J α 39. Data shown in *B–E* are representative of at least three independent experiments.




FIGURE 6. Activation of Ag-specific T cells in 172.10 TCR β -chain tg mice following immunization with MBP1–9[4Y]. LN cells were stained with PerCP-labeled anti-CD4, FITC-labeled anti-V α 2, PE-labeled 4Y:I-A^u tetramers, and allophycocyanin-labeled anti-CD62L before immunization (naïve) or after 3, 5, 7, and 11 days of immunization with 200 μ g of MBP1–9[4Y]. *A*, Upper panels, tetramer staining of CD4⁺ cells; lower panels, CD62L expression on CD4⁺, tetramer-positive populations (on naïve cells and day 5 postimmunization). *B*, CD62L down-regulation, represented as the percentage of CD62L^{low} cells, for CD4⁺ tetramer⁺V α 2⁺ populations and CD4⁺ tetramer⁺ V α 2⁻ populations at day 0 (naïve), days 3, 5, 7, and 11 postimmunization. For each day of analysis, LN cells from two mice were pooled. Data are representative of three independent experiments.

relative affinities that are similar (RDP-1) and ~50 fold lower (MBP68–80) than the binding of MBP1–9[4Y] (56). The recombinant proteins were expressed, purified, and cleaved by protease in the presence of MBP1–9[4Y] or OVA323–339, in an analogous way to that described for the CLIP:I-A^u complexes. Plate-bound complexes were used to stimulate hybridomas 2, 10, and 20 or the WT and Y95A transfectants (Fig. 7 and data not shown). Both RDP-1/4Y:I-A^u and MBP68–80/4Y:I-A^u complexes had similar properties to those seen for CLIP/4Y:I-A^u complexes. Thus, the distinct conformers appear to be induced by the binding of relatively low affinity peptides during biosynthesis followed by their displacement *in vitro*. However, low affinity binding of peptide during biosynthesis is alone insufficient to induce this conformer, as recombinant 4K:I-A^u complexes containing the low affinity WT N-terminal MBP peptide (position 4 is lysine; this peptide has an at least 1000-fold lower relative affinity than RDP-1 and MBP1–9[4Y] for I-A^u (49, 55, 56)) have stimulatory properties that are qualitatively similar to those of 4Y:I-A^u complexes (Fig. 7). The higher doses of recombinant protein that are needed to achieve T

cell stimulation by 4K:I-A^u complexes are consistent with our earlier observations describing the instability of peptide:I-A^u complexes made with the WT N-terminal epitope of MBP (53).

Location of the site of the conformational difference

The 1934.4 TCR has been previously shown to cross-react with MBP1–9 or MBP1–9[4Y] analogues with substitutions of the T cell contact residue at position 3 (Gln) by phenylalanine, tyrosine, histidine, and methionine (48). Therefore, comparison of the fine specificity of Ag recognition by WT and Y95A transfectants might allow us to map the contact site of the region encompassing Y95 (WT) or A95 (Y95A mutant) of the TCR on MBP1–9[4Y]:I-A^u complexes. MBP1–9[4Y] analogues with position 3 substitutions were used to pulse Utm6.15 cells and IL-2 secretion by WT and Y95A transfectants were quantitated (Fig. 8). The analyses show that compared with WT, Y95A transfectants are less responsive to all of the position 3 substituted analogues. In particular, they are significantly less responsive to MBP1–9[3Y,4Y]. The x-ray crystallographic structure of the recombinant 4Y:I-A^u complex (54)

FIGURE 7. Effects of prebinding of irrelevant peptides to I-A^u followed by their displacement by MBP1–9[4Y] on T cell recognition and stimulatory properties of 4K:I-A^u complexes. IL-2 levels were quantitated following stimulation of T cell hybridomas with: *A*, plate-bound RDP-1/4Y:I-A^u complexes generated by rhinovirus 3C protease cleavage of RDP-1:I-A^u complexes and replacement of RDP-1 by MBP1–9[4Y]; *B*, plate-bound RDP-1/OVA:I-A^u complexes generated as in *A* but with replacement of RDP-1 by OVA323–339; *C*, plate-bound 4Y:I-A^u complexes; *D*, plate-bound 4K:I-A^u complexes. The HRC.1 hybridoma (50) was used as a negative control. Data shown are representative of at least three independent experiments.





FIGURE 8. Recognition of position 3 analogues of MBP1–9[4Y] by transfectants expressing WT and Y95A TCRs. *A*, WT or Y95A transfectants were incubated with Utm6.15 cells pulsed with MBP1–9[4Y] or position 3 analogues (2 or 0.2 $\mu\text{g/ml}$) and IL-2 levels were quantitated. Position 3 analogues of MBP1–9[4Y] are abbreviated as follows: 3Q = WT residue; 3F = MBP1–9[3F,4Y] etc. *B*, α -Carbon trace of 4Y:I-A^u complex (54). The location of residue 3 of MBP (arrow) and flanking residues of α 1 (61–68) and β 1 helices (66–74) are indicated in black. The figure was drawn using RASMOL (courtesy of R. Sayle, Bioinformatics Research Institute, University of Edinburgh). Data are representative of four independent experiments.



demonstrates that the antigenic peptide is shifted toward one end of the peptide binding groove of I-A^u, leaving the P1 and P2 pockets unoccupied (Fig. 8). This shifting of peptide register in the groove results in a more central location of the third residue of MBP than if it were in a more conventional register. Thus, based on the orientation of TCR on pMHC in crystallographically solved TCR-pMHC complexes (36–40) it is plausible that the CDR3 α residue, Y95, contacts this region of the peptide. By extension, this suggests that the region of I-A^u that differs in the two pMHC conformers is in the vicinity of MBP residue 3 and encompasses residues 61–68 of the α 1 helix and residues 66–74 of the β 1 helix (Fig. 8).

Discussion

In the current study, an analysis of the functional effects of mutations of CDR residues of the 1934.4 TCR V α domain has led to the analysis of two possible conformers of the MHC class II molecule, I-A^u. The 1934.4 TCR is representative of the receptors borne by encephalitogenic T cells in H-2^u mice and recognizes the N-terminal epitope of MBP associated with the class II molecule I-A^u (44, 46). Mutated TCRs have been expressed in transfectants and responsiveness to Ag analyzed. “Functional avidity” of the transfectants has been compared with TCR-pMHC (“intrinsic”) avidity by assessing the binding of tetrameric 4Y:I-A^u complexes comprising MBP1–11[4Y] tethered to I-A^u. Generally, the correlation between functional and intrinsic avidity is high. However, mutation of the CDR3 α residue, Y95, to alanine (Y95A) results in an outlier. This mutation generates a TCR that binds tetramer slightly better than the WT TCR and yet is significantly less responsive to professional APCs pulsed with peptide Ag. Unexpectedly, Y95A transfectants are slightly more responsive than WT cells to Ag-pulsed, unconventional APCs expressing I-A^u. Therefore, the Y95A TCR senses conformational differences between pMHC ligands generated on the surface of professional vs unconventional APCs. Significantly, these two pMHC conformers can also be distinguished by Ag-specific T cells isolated from immunized H-2^u mice.

An obvious distinction between professional and unconventional APCs is that they differ in the expression of Ii. Initially, we

therefore investigated a role for the Ii-derived peptide, CLIP, which binds to the MHC class II groove (4, 5) in shaping the conformation of I-A^u. The CLIP:I-A^u interaction has been extensively investigated in earlier studies (67–69) and a model for CLIP:I-A^u built (70). CLIP dissociates more rapidly from I-A^u than OVA323–339 (68), and competes with biotinylated OVA323–339 for binding to I-A^u slightly less well than unlabeled OVA323–339 (67). Taken together with the report that the relative affinity of OVA323–339 is 3- to 4-fold higher (3- to 4-fold lower IC₅₀) for binding to I-A^u than that of MBP1–9[4Y] (56), this suggests that the affinity of MBP1–9[4Y] and CLIP for I-A^u fall in a similar range. By generating recombinant CLIP:I-A^u complexes in which CLIP can be replaced by MBP1–9[4Y], we have obtained support for the concept that CLIP prebinding can affect the conformation of the peptide:I-A^u complex that is subsequently formed by peptide exchange. However, the effect of CLIP is not specific: expression of recombinant peptide:I-A^u complexes containing either MBP68–80 or RDP-1 followed by their displacement by MBP1–9[4Y] also generates complexes which resemble those on the surface of peptide-pulsed, professional APCs. Thus, preloading by any (relatively weakly bound) peptide followed by displacement in vitro results in these types of complexes. This mode of peptide loading most likely involves a peptide receptive state of I-A^u, which is similar to that described by others for I-E and DR molecules (21, 22).

Analogous to the CLIP, RDP-1, or MBP68–80:I-A^u complexes that are subsequently loaded in vitro with MBP1–9[4Y], peptide loading onto I-A^u on the surface of APCs presumably occurs via displacement of weakly bound peptides or interaction with empty, unstable I-A^u molecules which would be expected to be transient (21, 22). These MHC molecules would be predicted to have relatively weakly bound peptides and, as a result, are targets for binding by exogenous peptides. During this “second round” of peptide loading, such complexes may evade H2-M editing through either Ag loading on the cell surface or the endosomal recycling pathway (14), although recent data support the possibility that editing can also occur during these Ag-loading pathways (16). We would expect complexes generated by peptide pulsing to be more open, in contrast to tighter, less flexible complexes that might form when

recombinant (4Y:I-A^u) protein traverses the secretory pathway with antigenic peptide covalently tethered. In this context, although tighter 4Y:I-A^u complexes do not form SDS-resistant compact dimers (52), they are more stable upon long-term storage (>2 mo) at 4°C than CLIP/4Y:I-A^u complexes (our unpublished observations). However, the question still remains as to how peptide loading onto I-A^u expressed by unconventional APCs (Utm6.15) results in what appears to be the tighter conformer, and we currently do not have an explanation for this.

The presumptive tight and open conformers that we have described are reminiscent of the type A and B complexes, respectively, described by Unanue and colleagues (29, 30, 32). However, there is a notable difference. The T cells that we have analyzed all recognize tight (type A) complexes, but only a subset respond well to the more open (type B) complexes, whereas the reverse appears to be the case for the studies of Unanue and colleagues (29, 30, 32). The reasons for this are currently unclear, but may relate to differences in the nature of Ag which in turn could affect repertoire selection. In two recent studies it has been shown that I-A^k-restricted type B cells specific for dominant epitopes derived from transgenically expressed hen egg lysozyme (residues 46–61) or autologous Aβ^k (residues 37–53) are not tolerated and enter the periphery, whereas type A cells are negatively selected (30, 33). In contrast, due to the low affinity of MBP1–9 for I-A^u (49, 55, 56), Ag-specific T cells escape negative selection and immunodominance to this epitope is seen following MBP immunization (71, 72). Thus, for this epitope, both type A and B cells could contribute to the peripheral T cell repertoire. A second, but not mutually exclusive, reason for the difference is that distinct I-A haplotypes are being compared which most likely have different intrinsic stabilities and biochemical properties (49, 73). It is also possible that the conformers we have described bear some similarity to the short- and long-lived isomers of MBP1–14 (and analogues) bound to I-A^k that can be distinguished by specific T cells (19). Further studies will be necessary to characterize the different pMHC conformers and to evaluate their interrelatedness in distinct Ag recognition systems.

Toward identifying the conformationally distinct region in the I-A^u conformers, we have mapped the interaction site for residue 95 of the 1934.4 Vα domain on cognate ligand. This has been conducted by comparing the recognition of position 3 analogues of MBP1–9[4Y] by transfectants expressing the WT 1934.4 TCR and Y95A mutant. Y95 appears to contact ligand in the region encompassing Gln3 of MBP1–9. From the recent x-ray structure of recombinant 4Y:I-A^u complexes (54) this residue is in the vicinity of residues 60–68 of the α1 helix and 65–74 of the β1 helix (Fig. 8). The shift in register of the MBP peptide in the I-A^u groove results in a more central location for MBP-Gln3 than would otherwise be seen (54, 74). Interaction of Y95 with ligand in this region would also be predicted from the diagonal orientation of the TCR on cognate ligand observed in x-ray structures of TCR-pMHC complexes in distinct Ag recognition systems (36–40). Comparison of the x-ray crystallographic structure of CLIP-DR1 and a hemagglutinin peptide-DR3 complex (75) indicate variations in conformation in the corresponding region of the DR molecule. Furthermore, analyses of the conformations of I-A^b induced by the binding of peptides of different affinities for this MHC molecule have shown that peptide (including CLIP) binding can modulate a similar region of the β-chain of I-A^b (34). Taken together, the data are therefore consistent with the concept that this region of MHC class II is flexible and subject to conformational variation.

Our observations concerning the properties of recombinant 4Y:I-A^u complexes have important implications for the detection of Ag-specific T cells using tetrameric/multimeric pMHC class II li-

gands (53, 62, 64, 76, 77). There may be a subset of Ag-specific (CD4⁺) T cells for which these engineered reagents do not yield correlative data between the characteristics of the TCR-pMHC interaction and Ag responsiveness. For example, we show that 4Y:I-A^u tetramers bind well to a subset of Ag-specific T cells that do not recognize pMHC complexes efficiently on the surface of peptide-pulsed (professional) APCs. This lack of correlation between tetramer staining vs responsiveness is seen for both the Y95A transfectant and a subset of T cells isolated from 172.10 TCR β-chain transgenic mice following immunization with MBP1–9[4Y]. How do T cells that poorly recognize the conformer induced by peptide loading onto APCs become activated and expanded, albeit inefficiently, following immunization with MBP1–9[4Y]? It is possible that a subset of APCs *in vivo* may express I-A^u conformers that resemble those on the surface of unconventional APCs used in this study (Utm6.15 cells) and this will be an area of future investigation.

Our study also has relevance to understanding the contribution of CDRα residues to Ag recognition. Analysis of the effects of CDR mutations demonstrate that the three central residues of CDR2 (R51, D52, and K53) make important contributions to the functional avidity of the 1934.4 TCR. Conservative changes of R51 and D52 to K51 and E52, respectively, result in substantial decreases in Ag responsiveness and binding by 4Y:I-A^u tetramers. The K53A mutation has an intermediate effect on functional activity. X-ray structural studies of TCR-pMHC class I and class II complexes have shown that residues in the CDR2α loop invariably contact ligand, with MHC rather than peptide contacts predominating (36–40). Specific residues in this CDR affect the efficiency of selection of thymocytes into the CD4 or CD8 lineage (42). In distinct recognition systems, CDR2α residues can modulate TCR-pMHC affinity or T cell responsiveness, including Th1/Th2 differentiation (78–80). Our recent x-ray structure of the 4Y:I-A^u complex showed that the P1 and P2 pockets of the I-A^u binding groove are not occupied by peptide (54). As a consequence of the shifted peptide, CDR1α contacts with peptide would be highly improbable if the 1934.4 TCR orientation on this pMHC ligand is similar to that in structurally solved TCR-pMHC complexes (36–40). Relatively strong CDR2α-MHC contacts, although not providing specificity for peptide, might therefore be needed to achieve the necessary affinity for T cell activation by MBP1–9:I-A^u-specific T cells.

A critical role for CDR3α residues of the TCR in peptide recognition has been shown in other Ag systems in both structural (36–40) and functional studies (81, 82). CDR3α residues of the 1934.4 TCR play a similarly important contribution: alteration of N94 to alanine completely ablates Ag recognition whereas the Y95A mutation has variable effects. Furthermore, our data suggest that the CDR3α loop is in proximity to residue 3 of MBP1–9 which has a central location in the I-A^u groove (54, 74) (Fig. 8).

In summary, our analyses indicate that two conformers of MBP1–9:I-A^u complexes can be distinguished by closely related TCRs. The analysis of the fine specificities of two TCRs which differ by only one CDR3α residue (Y95) has allowed us to map the region of conformational variation on the pMHC complex. We have also shown that the two distinct conformers can be produced in recombinant form in insect cells by manipulating the conditions of expression and antigenic peptide loading. Future work will be directed toward investigating how recognition of these distinct conformers might contribute toward autoimmunity in murine EAE.

Acknowledgments

We are indebted to Jing Tan and James Johnson for excellent technical assistance. We thank Dr. Joan Goverman for generously providing 172.10

TCR β -chain transgenic mice. We thank Dr. Emil Unanue for helpful discussions concerning pMHC conformers.

References

- Roche, P. A., M. S. Marks, and P. Cresswell. 1991. Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain. *Nature* 354:392.
- Amigorena, S., J. R. Drake, P. Webster, and I. Mellman. 1994. Transient accumulation of new class II MHC molecules in a novel endocytic compartment in B lymphocytes. *Nature* 369:113.
- Calafat, J., M. Nijenhuis, H. Janssen, A. Tulp, S. Dusseljee, R. Wubbolts, and J. Neefjes. 1994. Major histocompatibility complex class II molecules induce the formation of endocytic MIIC-like structures. *J. Cell Biol.* 126:967.
- Riberdy, J. M., J. R. Newcomb, M. J. Surman, J. A. Barbosa, and P. Cresswell. 1992. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. *Nature* 360:474.
- Romagnoli, P., and R. N. Germain. 1994. The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy. *J. Exp. Med.* 180:1107.
- Ericson, M. L., M. Sundstrom, D. M. Sansom, and D. J. Charron. 1994. Mutually exclusive binding of peptide and invariant chain to major histocompatibility complex class II antigens. *J. Biol. Chem.* 269:26531.
- Bijlmakers, M. J., P. Benaroch, and H. L. Ploegh. 1994. Assembly of HLA DR1 molecules translated in vitro: binding of peptide in the endoplasmic reticulum precludes association with invariant chain. *EMBO J.* 13:2699.
- Weber, D. A., B. D. Evavold, and P. E. Jensen. 1996. Enhanced dissociation of HLA-DR-bound peptides in the presence of HLA-DM. *Science* 274:618.
- Sloan, V. S., P. Cameron, G. Porter, M. Gammon, M. Amaya, E. Mellins, and D. M. Zaller. 1995. Mediation by HLA-DM of dissociation of peptides from HLA-DR. *Nature* 375:802.
- Denzin, L. K., C. Hammond, and P. Cresswell. 1996. HLA-DM interactions with intermediates in HLA-DR maturation and a role for HLA-DM in stabilizing empty HLA-DR molecules. *J. Exp. Med.* 184:2153.
- Pond, L., and C. Watts. 1997. Characterization of transport of newly assembled, T cell-stimulatory MHC class II-peptide complexes from MHC class II compartments to the cell surface. *J. Immunol.* 159:543.
- Raposo, G., H. W. Nijman, W. Stoorvogel, R. Liejendekker, C. V. Harding, C. J. Melief, and H. J. Geuze. 1996. B lymphocytes secrete antigen-presenting vesicles. *J. Exp. Med.* 183:1161.
- Babbitt, B. P., G. Matsueda, E. Haber, E. R. Unanue, and P. M. Allen. 1986. Antigenic competition at the level of peptide-Ia binding. *Proc. Natl. Acad. Sci. USA* 83:4509.
- Pinet, V., M. S. Malnati, and E. O. Long. 1994. Two processing pathways for the MHC class II-restricted presentation of exogenous influenza virus antigen. *J. Immunol.* 152:4852.
- Lindner, R., and E. R. Unanue. 1996. Distinct antigen MHC class II complexes generated by separate processing pathways. *EMBO J.* 15:6910.
- Santambrogio, L., A. K. Sato, G. J. Carven, S. L. Belyanskaya, J. L. Strominger, and L. J. Stern. 1999. Extracellular antigen processing and presentation by immature dendritic cells. *Proc. Natl. Acad. Sci. USA* 96:15056.
- Sadegh-Nasseri, S., and H. M. McConnell. 1989. A kinetic intermediate in the reaction of an antigenic peptide and I-E^k. *Nature* 337:274.
- Sadegh-Nasseri, S., and R. N. Germain. 1991. A role for peptide in determining MHC class II structure. *Nature* 353:167.
- Rabinowitz, J. D., K. Tate, C. Lee, C. Beeson, and H. M. McConnell. 1997. Specific T cell recognition of kinetic isomers in the binding of peptide to class II major histocompatibility complex. *Proc. Natl. Acad. Sci. USA* 94:8702.
- Schmitt, L., J. J. Boniface, M. M. Davis, and H. M. McConnell. 1998. Kinetic isomers of a class II MHC-peptide complex. *Biochemistry* 37:17371.
- Rabinowitz, J. D., M. Vrljic, P. M. Kason, M. N. Liang, R. Busch, J. J. Boniface, M. M. Davis, and H. M. McConnell. 1998. Formation of a highly peptide-receptive state of class II MHC. *Immunity* 9:699.
- Natarajan, S. K., M. Assadi, and S. Sadegh-Nasseri. 1999. Stable peptide binding to MHC class II molecule is rapid and is determined by a receptive conformation shaped by prior association with low affinity peptides. *J. Immunol.* 162:4030.
- Zarutskie, J. A., A. K. Sato, M. M. Rushe, I. C. Chan, A. Lomakin, G. B. Benedek, and L. J. Stern. 1999. A conformational change in the human major histocompatibility complex protein HLA-DR1 induced by peptide binding. *Biochemistry* 38:5878.
- Peterson, M., and J. Miller. 1990. Invariant chain influences the immunological recognition of MHC class II molecules. *Nature* 345:172.
- Viville, S., J. Neefjes, V. Lotteau, A. Dierich, M. Lemeur, H. Ploegh, C. Benoist, and D. Mathis. 1993. Mice lacking the MHC class II-associated invariant chain. *Cell* 72:635.
- Bikoff, E. K., L. Y. Huang, V. Episkopou, J. van Meerwijk, R. N. Germain, and E. J. Robertson. 1993. Defective major histocompatibility complex class II assembly, transport, peptide acquisition, and CD4⁺ T cell selection in mice lacking invariant chain expression. *J. Exp. Med.* 177:1699.
- Witt, S. N., and H. M. McConnell. 1994. Formation and dissociation of short-lived class II MHC-peptide complexes. *Biochemistry* 33:1861.
- Boniface, J. J., D. S. Lyons, D. A. Wettstein, N. L. Allbritton, and M. M. Davis. 1996. Evidence for a conformational change in a class II major histocompatibility complex molecule occurring in the same pH range where antigen binding is enhanced. *J. Exp. Med.* 183:119.
- Viner, N. J., C. A. Nelson, B. Deck, and E. R. Unanue. 1996. Complexes generated by the binding of free peptides to class II MHC molecules are antigenically diverse compared with those generated by intracellular processing. *J. Immunol.* 156:2365.
- Peterson, D. A., R. J. DiPaolo, O. Kanagawa, and E. R. Unanue. 1999. Quantitative analysis of the T cell repertoire that escapes negative selection. *Immunity* 11:453.
- Gyotoku, T., Y. Fukui, and T. Sasazuki. 1998. An endogenously processed self peptide and the corresponding exogenous peptide bound to the same MHC class II molecule could be distinct ligands for TCR with different kinetic stability. *Eur. J. Immunol.* 28:4050.
- Unanue, E. R. 2002. Perspective on antigen processing and presentation. *Immunol. Rev.* 185:86.
- Lovitch, S. B., J. J. Walters, M. L. Gross, and E. R. Unanue. 2003. APCs present A β^k derived peptides that are autoantigenic to type B T cells. *J. Immunol.* 170:4155.
- Chervonsky, A. V., R. M. Medzhitov, L. K. Denzin, A. K. Barlow, A. Y. Rudensky, and C. A. Janeway, Jr. 1998. Subtle conformational changes induced in major histocompatibility complex class II molecules by binding peptides. *Proc. Natl. Acad. Sci. USA* 95:10094.
- Viret, C., X. He, and C. A. Janeway, Jr. 2003. Altered positive selection due to corecognition of floppy peptide/MHC II conformers supports an integrative model of thymic selection. *Proc. Natl. Acad. Sci. USA* 100:5354.
- Garcia, K. C., M. Degano, R. L. Stanfield, A. Brunmark, M. R. Jackson, P. A. Peterson, L. Teyton, and I. A. Wilson. 1996. An $\alpha\beta$ T cell receptor structure at 2.5 Å and its orientation in the TCR-MHC complex. *Science* 274:209.
- Garboczi, D. N., P. Ghosh, U. Utz, Q. R. Fan, W. E. Biddison, and D. C. Wiley. 1996. Structure of the complex between human T-cell receptor, viral peptide and HLA-A2. *Nature* 384:134.
- Reinherz, E. L., K. Tan, L. Tang, P. Kern, J. Liu, Y. Xiong, R. E. Hussey, A. Smolyar, B. Hare, R. Zhang, et al. 1999. The crystal structure of a T cell receptor in complex with peptide and MHC class II. *Science* 286:1913.
- Ding, Y. H., K. J. Smith, D. N. Garboczi, U. Utz, W. E. Biddison, and D. C. Wiley. 1998. Two human T cell receptors bind in a similar diagonal mode to the HLA-A2/Tax peptide complex using different TCR amino acids. *Immunity* 8:403.
- Hennecke, J., A. Carfi, and D. C. Wiley. 2000. Structure of a covalently stabilized complex of a human $\alpha\beta$ T-cell receptor, influenza HA peptide and MHC class II molecule, HLA-DR1. *EMBO J.* 19:5611.
- Fields, B. A., B. Ober, E. L. Malchiodi, M. I. Lebedeva, B. C. Braden, X. Ysern, J. K. Kim, X. Shao, E. S. Ward, and R. A. Mariuzza. 1995. Crystal structure of the Va domain of a T cell antigen receptor. *Science* 270:1821.
- Sim, B. C., L. Zerva, M. I. Greene, and N. R. J. Gascoigne. 1996. Control of MHC restriction by TCR Va CDR1 and CDR2. *Science* 273:963.
- Sant'Angelo, D. B., B. Lucas, P. G. Waterbury, B. Cohen, T. Brabb, J. Goverman, R. N. Germain, and C. A. J. Janeway. 1998. A molecular map of T cell development. *Immunity* 9:179.
- Acha-Orbea, H., D. J. Mitchell, L. Timmermann, D. C. Wraith, G. S. Tausch, M. K. Waldor, S. S. Zamvil, H. O. McDevitt, and L. Steinman. 1988. Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention. *Cell* 54:263.
- Wraith, D. C., D. E. Smilek, D. J. Mitchell, L. Steinman, and H. O. McDevitt. 1989. Antigen recognition in autoimmune encephalomyelitis and the potential for peptide-mediated immunotherapy. *Cell* 59:247.
- Zamvil, S. S., D. J. Mitchell, A. C. Moore, K. Kitamura, L. Steinman, and J. B. Rothbard. 1986. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. *Nature* 324:258.
- Goverman, J., A. Woods, L. Larson, L. P. Weiner, L. Hood, and D. M. Zaller. 1993. Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. *Cell* 72:551.
- Wraith, D. C., B. Bruun, and P. J. Fairchild. 1992. Cross-reactive antigen recognition by an encephalitogenic T cell receptor: implications for T cell biology and autoimmunity. *J. Immunol.* 149:3765.
- Mason, K., D. W. J. Denney, and H. M. McConnell. 1995. Myelin basic protein peptide complexes with the class II MHC molecules I-A^u and I-A^k form and dissociate rapidly at neutral pH. *J. Immunol.* 154:5216.
- Corthay, A., J. Backlund, J. Broddefalk, E. Michaelsson, T. J. Goldschmidt, J. Kihlberg, and R. Holmdahl. 1998. Epitope glycosylation plays a critical role for T cell recognition of type II collagen in collagen-induced arthritis. *Eur. J. Immunol.* 28:2580.
- Thatte, J., A. Qadri, C. Radu, and E. S. Ward. 1999. Molecular requirements for T cell recognition by a major histocompatibility complex class II-restricted T cell receptor: the involvement of the fourth hypervariable loop of the Va domain. *J. Exp. Med.* 189:509.
- Radu, C. G., B. T. Ober, L. Colantonio, A. Qadri, and E. S. Ward. 1998. Expression and characterization of recombinant soluble peptide: I-A complexes associated with murine experimental autoimmune diseases. *J. Immunol.* 160:5915.
- Radu, C. G., S. M. Anderton, M. Firan, D. C. Wraith, and E. S. Ward. 2000. Detection of autoreactive T cells in H-2^u mice using peptide-MHC multimers. *Int. Immunol.* 12:1553.
- He, X., C. Radu, J. Sidney, A. Sette, E. S. Ward, and K. C. Garcia. 2002. Structural snapshot of aberrant antigen presentation linked to autoimmunity: the immunodominant epitope of MBP complexed with I-A^u. *Immunity* 17:83.
- Fairchild, P. J., R. Wildgoose, E. Atherton, S. Webb, and D. C. Wraith. 1993. An autoantigenic T cell epitope forms unstable complexes with class II MHC: a novel route for escape from tolerance induction. *Int. Immunol.* 5:1151.
- Fugger, L., J. Liang, A. Gautam, J. B. Rothbard, and H. O. McDevitt. 1996. Quantitative analysis of peptides from myelin basic protein binding to the MHC class II protein, I-A^u, which confers susceptibility to experimental allergic encephalomyelitis. *Mol. Med.* 2:181.

57. Koch, N., W. Lauer, J. Habicht, and B. Dobberstein. 1987. Primary structure of the gene for the murine Ia antigen-associated invariant chains (Ii): an alternatively spliced exon encodes a cysteine-rich domain highly homologous to a repetitive sequence of thyroglobulin. *EMBO J.* 6:1677.
58. Qadri, A., C. G. Radu, J. Thatte, P. Cianga, B. T. Ober, R. J. Ober, and E. S. Ward. 2000. A role for the region encompassing the c⁺ strand of a TCR V α domain in T cell activation events. *J. Immunol.* 165:820.
59. Garcia, K. C., C. Radu, J. Ho, R. J. Ober, and E. S. Ward. 2001. Kinetics and thermodynamics of T cell receptor-autoantigen interactions in murine experimental autoimmune encephalomyelitis. *Proc. Natl. Acad. Sci. USA* 98:6818.
60. Kruisbeek, A. M. 1990. Production of mouse T cell hybridomas. In *Current Protocols in Immunology*. J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober, eds. John Wiley and Sons, p. 3.14.
61. Anderton, S. M., C. G. Radu, P. A. Lowrey, E. S. Ward, and D. C. Wraith. 2001. Negative selection during the peripheral immune response to antigen. *J. Exp. Med.* 193:1.
62. Crawford, F., H. Kozono, J. White, P. Marrack, and J. Kappler. 1998. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. *Immunity* 8:675.
63. Busch, D. H., and E. G. Pamer. 1999. T cell affinity maturation by selective expansion during infection. *J. Exp. Med.* 189:701.
64. Savage, P. A., J. J. Boniface, and M. M. Davis. 1999. A kinetic basis for T cell receptor repertoire selection during an immune response. *Immunity* 10:485.
65. Qadri, A., J. Thatte, C. G. Radu, B. Ober, and E. S. Ward. 1999. Characterization of the interaction of a TCR α chain variable domain with MHC II I-A molecules. *Int. Immunol.* 11:967.
66. Urban, J. L., V. Kumar, D. H. Kono, C. Gomez, S. J. Horvath, J. Clayton, D. G. Ando, E. E. Sercarz, and L. Hood. 1988. Restricted use of T cell receptor V genes in murine autoimmune encephalomyelitis raises possibilities for antibody therapy. *Cell* 54:577.
67. Gautam, A. M., C. Pearson, V. Quinn, H. O. McDevitt, and P. J. Milburn. 1995. Binding of an invariant-chain peptide, CLIP, to I-A major histocompatibility complex class II molecules. *Proc. Natl. Acad. Sci. USA* 92:335.
68. Liang, M. N., C. Beeson, K. Mason, and H. M. McConnell. 1995. Kinetics of the reactions between the invariant chain (85–99) peptide and proteins of the murine class II MHC. *Int. Immunol.* 7:1397.
69. Gautam, A. M., M. Yang, P. J. Milburn, R. Baker, A. Bhatnagar, J. McCluskey, and T. Boston. 1997. Identification of residues in the class II-associated Ii peptide (CLIP) region of invariant chain that affect efficiency of MHC class II-mediated antigen presentation in an allele-dependent manner. *J. Immunol.* 159:2782.
70. Lee, C., and H. M. McConnell. 1995. A general model of invariant chain association with class II major histocompatibility complex proteins. *Proc. Natl. Acad. Sci. USA* 92:8269.
71. Liu, G. Y., P. J. Fairchild, R. M. Smith, J. R. Prowle, D. Kioussis, and D. C. Wraith. 1995. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. *Immunity* 3:407.
72. Harrington, C. J., A. Paez, T. Hunkapiller, V. Mannikko, T. Brabb, M. Ahearn, C. Beeson, and J. Goverman. 1998. Differential tolerance is induced in T cells recognizing distinct epitopes of myelin basic protein. *Immunity* 8:571.
73. Carrasco-Marin, E., J. Shimizu, O. Kanagawa, and E. R. Unanue. 1996. The class II MHC I-A^{g7} molecules from non-obese diabetic mice are poor peptide binders. *J. Immunol.* 156:450.
74. Lee, C., M. N. Liang, K. M. Tate, J. D. Rabinowitz, C. Beeson, P. P. Jones, and H. M. McConnell. 1998. Evidence that the autoimmune antigen myelin basic protein (MBP) Ac1–9 binds towards one end of the major histocompatibility complex (MHC) cleft. *J. Exp. Med.* 187:1505.
75. Ghosh, P., M. Amaya, E. Mellins, and D. C. Wiley. 1995. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. *Nature* 378:457.
76. Gutgemann, I., A. M. Fahrner, J. D. Altman, M. M. Davis, and Y. H. Chien. 1998. Induction of rapid T cell activation and tolerance by systemic presentation of an orally administered antigen. *Immunity* 8:667.
77. Liu, C. P., K. Jiang, C. H. Wu, W. H. Lee, and W. J. Lin. 2000. Detection of glutamic acid decarboxylase-activated T cells with I-A^{g7} tetramers. *Proc. Natl. Acad. Sci. USA* 97:14596.
78. Hong, S. C., A. Chelouche, R. H. Lin, D. Shaywitz, N. S. Braunstein, L. Glimcher, and C. A. J. Janeway. 1992. An MHC interaction site maps to the amino-terminal half of the T cell receptor α chain variable domain. *Cell* 69:999.
79. Manning, T. C., C. J. Schlueter, T. C. Brodnicki, E. A. Parke, J. A. Speir, K. C. Garcia, L. Teyton, I. A. Wilson, and D. M. Kranz. 1998. Alanine scanning mutagenesis of an $\alpha\beta$ T cell receptor: mapping the energy of antigen recognition. *Immunity* 8:413.
80. Blander, J. M., D. B. Sant'Angelo, K. Bottomly, and C. A. Janeway, Jr. 2000. Alteration at a single amino acid residue in the T cell receptor α chain complementarity determining region 2 changes the differentiation of naive CD4 T cells in response to antigen from T helper cell type 1 (Th1) to Th2. *J. Exp. Med.* 191:2065.
81. Engel, I., and S. M. Hedrick. 1988. Site-directed mutations in the VDJ junctional region of a T cell receptor β chain cause changes in antigenic peptide recognition. *Cell* 54:473.
82. Jorgensen, J. L., U. Esser, B. Fazekas de St. Groth, P. A. Reay, and M. M. Davis. 1992. Mapping T-cell receptor-peptide contacts by variant peptide immunization of single-chain transgenics. *Nature* 355:224.